RenovoRx, Inc. (RNXT) Form 8-K — Aug 12, 2026
RenovoRx posted record Q2 2026 revenue of $909,000, up approximately 61% sequentially and roughly 115% year over year, at an ~84% gross margin. The quarter alone represented about 83% of the company's entire 2025 revenue of $1.1 million. Management raised full-year 2026 revenue guidance to $3.75M-$4.25M from $3.0M-$4.0M, implying ~241%-286% growth. Active commercial cancer centers grew more than 30% quarter over quarter to 21, with a target of 36 by year-end, and the first commercial sarcoma case extends RenovoCath beyond pancreatic cancer.
Key figures
- Revenue
- 909000
- Guidance
- FY2026 revenue guidance raised and tightened to $3.75M-$4.25M from prior $3.0M-$4.0M, implying ~241%-286% YoY growth vs FY2025 revenue of $1.1M
- Revenue Yoy
- 115%
- Total Assets
- 11472000
- Cash Position
- 9479000
- Shares Outstanding
- 45121982
- Cash Runway
- sufficient into second half of 2027
- H1 2026 revenue
- 1472000
- Pipeline Centers
- 63
- Rd Expense Q2 2026
- 1200000
- Sga Expense Q2 2026
- 2915000
- Gross Margin Q2 2026
- 84.3%
- Gross Profit Q2 2026
- 766000
- Tige RPa CCompletion
- first half 2027
- Active Cancer Centers
- 21
- Tige RPa CTopline Data
- second half 2027
- Tam Peak Annual Us Sales
- 400000000
- Tige RPa CEvents Observed
- 78 of 86 required events as of August 11, 2026
- Cash Flow Breakeven Target
- Q4 2027 at ~$5M quarterly revenue run-rate
- Expanded Peak Sales Potential
- 1000000000
- Target Active Centers By YE2026
- 36
- Procedures Since510k Clearance
- 900+
Price after filing
Close on the filing date to close N calendar days later (from $1.16). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.